Lenalidomide Stada

Lenalidomide, the active ingredient in Lenalidomide Stada, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, specifically multiple myeloma and myelodysplastic syndromes with deletion 5q, and is prescribed for adult patients under specialist supervision.

GNH USA supplies Lenalidomide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to hospitals, pharmacies and clinical trial sites.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders. - Multiple Myeloma: improves disease control and prolongs survival in patients with relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and can lead to cytogenetic remission. - Mantle Cell Lymphoma: used in relapsed or refractory cases to achieve tumor reduction.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: decreased neutrophil count. - Thrombocytopenia: reduced platelet levels. - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Rash: skin irritation. - Constipation: difficulty passing stool.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in veins. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers. - Hepatic failure: serious liver injury. - Tumor lysis syndrome: rapid tumor cell breakdown. - Anaphylaxis: life‑threatening allergic reaction.

When prescribing Lenalidomide, clinicians should observe several safety measures to minimize risk. - Pregnancy: contraindicated; teratogenic, use effective contraception. - Thromboembolism risk: assess and consider prophylactic anticoagulation. - Hematologic monitoring: regular CBC to detect neutropenia or thrombocytopenia. - Infection risk: monitor for signs of infection and manage promptly. - Renal impairment: adjust dose in patients with reduced kidney function. - Store at ambient temperature: keep below 25 °C, in original container, protect from moisture.

Lenalidomide interacts with several drug classes; awareness of these interactions helps avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs: additive risk of gastrointestinal bleeding. - Antiplatelet agents (e.g., aspirin): monitor for bleeding. - Hormonal contraceptives: reduced effectiveness, consider alternative methods. - Live vaccines: increased infection risk, avoid during therapy.